Why is the price-earnings ratio of Heyuan Biological so high?

The income contributed by the CDMO business of Heyuan Bio-gene Therapy has also increased significantly, from 65,438+0,296,5438+0,654,387,000 yuan in 2065 to 43.8+0.2 billion yuan in 2020, which has gradually become the company's main source of income, accounting for more than 70%. In terms of production scale, Heyuan Bio has nearly 4,500 integrated platforms for research and development of gene therapy vectors and 7,000 GMP platforms for gene therapy products, including plasmid production lines 1, virus vector production lines 3, CAR-T cell production lines 2, library building production lines 3 and filling production lines 1. The production scale of GMP has reached the level of similar foreign enterprises.

In addition, Heyuan Bio also plans to invest 654.38+0.5 billion yuan to build a precision medical industrial base in Zhi Zhi. After the project is completed, the GMP production line will be greatly expanded to further expand the production capacity.

With the gradual release of production capacity, it will also press the acceleration button for the future development of Heyuan Bio, and truly become the "first CDMO of gene therapy" that can lead the industry.